KIRA BELLAMY: Open Payments
NPI 1255085809 · WASHINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,699 in 303 payments from 17 companies in 2025. Trend: 2023 $2,845 · 2024 $4,709 · 2025 $6,699
Food & beverage: $6,615Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 64 | $1,677 |
| Madrigal Pharmaceuticals | 53 | $1,027 |
| Janssen Biotech, Inc. | 38 | $760 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 39 | $744 |
| PFIZER INC. | 24 | $556 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $523 |
| GENZYME CORPORATION | 10 | $374 |
| Ardelyx, Inc. | 11 | $256 |
| Phathom Pharmaceuticals, Inc. | 12 | $181 |
| Organon LLC | 5 | $113 |
Products named: REZDIFFRA, TREMFYA, XIFAXAN, RINVOQ, SKYRIZI, ENTYVIO, XELJANZ, DUPIXENT.
Industry payments across PA — which companies pay providers there.
